Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cytarabine

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with cytarabine in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)
Studies
(cytarabine)
Trials
(cytarabine)
Recent Studies (post-2010) (cytarabine)
9,15618755215,4872,4243,188

Protein Interaction Comparison

ProteinTaxonomy1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)cytarabine (IC50)
nuclear receptor coactivator 3 isoform aHomo sapiens (human)7.533
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)0.02

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boogaerts, M; Verhoef, G1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cytarabine

ArticleYear
Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome.
    American journal of hematology, 1991, Volume: 36, Issue:4

    Topics: Antigens, Differentiation; CD11 Antigens; CD18 Antigens; Cell Adhesion; Cytarabine; Dose-Response Relationship, Drug; Endothelium; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung; Male; Middle Aged; Neutrophils; Platelet Activating Factor; Receptors, Leukocyte-Adhesion; Respiratory Distress Syndrome; Superoxides; Tumor Necrosis Factor-alpha

1991